{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:11:23Z","timestamp":1788988283248,"version":"build-2803163510"},"reference-count":114,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["1451815"],"award-info":[{"award-number":["1451815"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000142","name":"Arthritis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000142","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006538","name":"Arthritis Society Canada","doi-asserted-by":"publisher","award":["23-0313"],"award-info":[{"award-number":["23-0313"]}],"id":[{"id":"10.13039\/501100006538","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.trecan.2026.04.010","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:30:02Z","timestamp":1779276602000},"page":"802-824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mouse models of immune-related adverse events: progress, challenges, and opportunities"],"prefix":"10.1016","volume":"12","author":[{"given":"Theodoros","family":"Papadopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madelyn J.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina L.","family":"Naranjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel F.","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Wilson H.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia V.","family":"Del Rinc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2026.04.010_bb0005","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.04.010_bb0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.04.010_bb0015","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.04.010_bb0020","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1158\/1078-0432.CCR-23-3296","article-title":"Tissue-resident T cells in clinical response and immune-related adverse events of immune checkpoint blockade","volume":"30","author":"Zhao","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.04.010_bb0025","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41416-024-02887-1","article-title":"Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review","volume":"132","author":"Jayathilaka","year":"2025","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.trecan.2026.04.010_bb0030","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.52302","article-title":"Immune-related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors","volume":"7","author":"Cook","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.trecan.2026.04.010_bb0035","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2026.04.010_bb0040","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4143\/crt.2020.790","article-title":"The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8,436 patients","volume":"53","author":"Tang","year":"2021","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.trecan.2026.04.010_bb0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.2668","article-title":"Late-onset immune-related adverse events after immune checkpoint inhibitor therapy","volume":"8","author":"Durbin","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.trecan.2026.04.010_bb0050","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2020.03.017","article-title":"Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors","volume":"132","author":"Maillet","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.trecan.2026.04.010_bb0055","article-title":"Understanding adverse events of immunotherapy: a mechanistic perspective","volume":"218","author":"Burke","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.trecan.2026.04.010_bb0060","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.trecan.2026.04.010_bb0065","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2026.04.010_bb0070","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-024-08105-5","article-title":"Immune responses in checkpoint myocarditis across heart, blood and tumour","volume":"636","author":"Blum","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.04.010_bb0075","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1158\/2326-6066.CIR-24-0011","article-title":"Molecular pathways and cellular subsets associated with adverse clinical outcomes in overlapping immune-related myocarditis and myositis","volume":"12","author":"Siddiqui","year":"2024","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.trecan.2026.04.010_bb0080","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.122.062551","article-title":"Expansion of pathogenic cardiac macrophages in immune checkpoint inhibitor myocarditis","volume":"149","author":"Ma","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.trecan.2026.04.010_bb0085","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1158\/2159-8290.CD-20-0856","article-title":"A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention","volume":"11","author":"Wei","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.04.010_bb0090","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","article-title":"T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis","volume":"611","author":"Axelrod","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.04.010_bb0095","doi-asserted-by":"crossref","first-page":"6640","DOI":"10.1038\/s41467-024-50996-5","article-title":"Gasdermin-E-mediated pyroptosis drives immune checkpoint inhibitor-associated myocarditis via cGAS-STING activation","volume":"15","author":"Sun","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.04.010_bb0100","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.4049\/jimmunol.2300841","article-title":"Murine MHC-deficient nonobese diabetic mice carrying human HLA-DQ8 develop severe myocarditis and myositis in response to anti-PD-1 immune checkpoint inhibitor cancer therapy","volume":"212","author":"Racine","year":"2024","journal-title":"J. Immunol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0105","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.cell.2020.06.001","article-title":"Molecular pathways of colon inflammation induced by cancer immunotherapy","volume":"182","author":"Luoma","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2026.04.010_bb0110","doi-asserted-by":"crossref","first-page":"11504","DOI":"10.3390\/ijms241411504","article-title":"Checkpoint inhibitor-induced colitis: from pathogenesis to management","volume":"24","author":"Terrin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.trecan.2026.04.010_bb0115","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1053\/j.gastro.2021.06.025","article-title":"Interferon-gamma-producing CD8+ tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor-colitis","volume":"161","author":"Sasson","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.trecan.2026.04.010_bb0120","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s43018-024-00810-4","article-title":"A targetable type III immune response with increase of IL-17A expressing CD4+ Tcells is associated with immunotherapy-induced toxicity in melanoma","volume":"5","author":"Dimitriou","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.trecan.2026.04.010_bb0125","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ccell.2025.01.004","article-title":"Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity","volume":"43","author":"Braun","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.04.010_bb0130","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/2326-6066.CIR-22-0362","article-title":"Checkpoint blockade-induced dermatitis and colitis are dominated by tissue-resident memory T cells and Th1\/Tc1 cytokines","volume":"10","author":"Reschke","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.trecan.2026.04.010_bb0135","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.04.010_bb0140","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009345","article-title":"Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"12","author":"Ju","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.04.010_bb0145","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.adh8342","article-title":"Microbiota-dependent activation of CD4+ T cells induces CTLA-4 blockade-associated colitis via Fc\u03b3 receptors","volume":"383","author":"Lo","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.trecan.2026.04.010_bb0150","doi-asserted-by":"crossref","first-page":"6719","DOI":"10.1038\/s41467-023-41798-2","article-title":"Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and is dependent on an IL23\/IFN\u03b3 axis","volume":"14","author":"Lo","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.04.010_bb0155","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.14336\/AD.2024.0546","article-title":"The roles of T cells in immune checkpoint inhibitor-induced arthritis","volume":"16","author":"Chen","year":"2024","journal-title":"Aging Dis."},{"key":"10.1016\/j.trecan.2026.04.010_bb0160","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1038\/s41467-024-46195-x","article-title":"Single-cell profiling identifies IL1Bhi macrophages associated with inflammation in PD-1 inhibitor-induced inflammatory arthritis","volume":"15","author":"Zhou","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.04.010_bb0165","article-title":"TNF-\u03b1 inhibitor ameliorates immune-related arthritis and pneumonitis in humanized mice","volume":"13","author":"Gao","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0170","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.anai.2021.02.009","article-title":"Immune-related cutaneous adverse events due to checkpoint inhibitors","volume":"126","author":"Wang","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0175","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1071983","article-title":"Cutaneous manifestations associated with immune checkpoint inhibitors","volume":"14","author":"Watanabe","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0180","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1158\/1078-0432.CCR-10-2463","article-title":"Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc\/IV melanoma","volume":"17","author":"Sarnaik","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.04.010_bb0185","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1158\/1078-0432.CCR-23-3431","article-title":"Immunologic profiling of immune-related cutaneous adverse events with checkpoint inhibitors reveals polarized actionable pathways","volume":"30","author":"Lacouture","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.04.010_bb0190","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4049\/jimmunol.1500448","article-title":"Cutting edge: PD-1 regulates imiquimod-induced psoriasiform dermatitis through inhibition of IL-17A expression by innate \u03b3\u03b4-low T cells","volume":"195","author":"Imai","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0195","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s42003-020-01308-2","article-title":"Activation of CD8 T cells accelerates anti-PD-1 antibody-induced psoriasis-like dermatitis through IL-6","volume":"3","author":"Tanaka","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0200","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","article-title":"Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury","volume":"31","author":"Zen","year":"2018","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0205","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1016\/j.apsb.2021.10.003","article-title":"Mechanisms of immune checkpoint inhibitor-mediated liver injury","volume":"11","author":"Shojaie","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.trecan.2026.04.010_bb0210","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/s41467-021-21572-y","article-title":"Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis","volume":"12","author":"Hutchinson","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.04.010_bb0215","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jhep.2021.02.008","article-title":"Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis","volume":"75","author":"Gudd","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217276","article-title":"Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice","volume":"14","author":"Affolter","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.trecan.2026.04.010_bb0225","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.jhep.2021.06.037","article-title":"T cells and monocyte-derived myeloid cells mediate immunotherapy-related hepatitis in a mouse model","volume":"75","author":"Llewellyn","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0230","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41419-024-06535-7","article-title":"Innate and adaptive immune cell interaction drives inflammasome activation and hepatocyte apoptosis in murine liver injury from immune checkpoint inhibitors","volume":"15","author":"Shojaie","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.trecan.2026.04.010_bb0235","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008078","article-title":"Therapeutic inhibition of monocyte recruitment prevents checkpoint inhibitor-induced hepatitis","volume":"12","author":"Gudd","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.04.010_bb0240","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg0675","article-title":"Clonally expanded, thyrotoxic effector CD8+ T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis","volume":"15","author":"Lechner","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2026.04.010_bb0245","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4049\/jimmunol.2200244","article-title":"Inhibition of IL-17A protects against thyroid immune-related adverse events while preserving checkpoint inhibitor antitumor efficacy","volume":"209","author":"Lechner","year":"2022","journal-title":"J. Immunol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0250","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.4049\/jimmunol.2001073","article-title":"Th17 cells contribute to the pathology of autoimmune hypophysitis","volume":"206","author":"Chalan","year":"2021","journal-title":"J. Immunol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0255","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2026.04.010_bb0260","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011818","article-title":"Autoimmune origin for immune checkpoint inhibitor-diabetes revealed by deep immune phenotyping of the pancreas","volume":"13","author":"Quandt","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.04.010_bb0265","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.156330","article-title":"Immune cells and their inflammatory mediators modify \u03b2 cells and cause checkpoint inhibitor-induced diabetes","volume":"7","author":"Perdigoto","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.trecan.2026.04.010_bb0270","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1425","article-title":"Diabetes induced by checkpoint inhibition in nonobese diabetic mice can be prevented or reversed by a JAK1\/JAK2 inhibitor","volume":"11","author":"Ge","year":"2022","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0275","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aas9673","article-title":"Location, location, location: tissue resident memory T cells in mice and humans","volume":"4","author":"Szabo","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0280","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41385-022-00491-1","article-title":"Regulation of tissue-resident memory T cells by the microbiota","volume":"15","author":"Overacre-Delgoffe","year":"2022","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0285","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/s41586-025-10001-5","article-title":"Environmentally driven immune imprinting protects against allergy","volume":"650","author":"Erickson","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.04.010_bb0290","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/2326-6066.CIR-24-0463","article-title":"Age-associated contraction of tumor-specific T cells impairs antitumor immunity","volume":"12","author":"Georgiev","year":"2024","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.trecan.2026.04.010_bb0295","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40425-014-0029-x","article-title":"The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer","volume":"2","author":"Stewart","year":"2014","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.04.010_bb0300","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1158\/1078-0432.CCR-18-0762","article-title":"Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers","volume":"25","author":"Sharma","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.04.010_bb0305","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1016\/j.cell.2021.05.027","article-title":"Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop","volume":"184","author":"Marangoni","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2026.04.010_bb0310","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011312","article-title":"Tumor location as a risk factor for severe immune-related adverse events","volume":"13","author":"Blum","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.04.010_bb0315","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s43018-024-00730-3","article-title":"Clinical and translational attributes of immune-related adverse events","volume":"5","author":"Suijkerbuijk","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.trecan.2026.04.010_bb0320","doi-asserted-by":"crossref","DOI":"10.1172\/JCI145186","article-title":"Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms","volume":"131","author":"Moslehi","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.trecan.2026.04.010_bb0325","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/RHU.0000000000001874","article-title":"Immune checkpoint inhibitor-associated myositis: a distinct form of inflammatory myopathy","volume":"28","author":"Saygin","year":"2022","journal-title":"J. Clin. Rheumatol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0330","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/MCG.0000000000001705","article-title":"Immunotherapy-induced colitis: a comprehensive review of epidemiology, clinical presentation, diagnostic workup, and management plan","volume":"56","author":"Vaziri","year":"2022","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0335","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1097\/RHU.0000000000001370","article-title":"Checkpoint inhibitor-associated arthritis: a systematic review of case reports and case series","volume":"27","author":"Ghosh","year":"2021","journal-title":"J. Clin. Rheumatol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0340","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jid.2021.06.040","article-title":"Immune checkpoint blockade and skin toxicity pathogenesis","volume":"142","author":"Ma","year":"2022","journal-title":"J. Invest Dermatol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0345","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/HEP.0000000000000045","article-title":"Checkpoint inhibitor hepatotoxicity: pathogenesis and management","volume":"79","author":"Cunningham","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.trecan.2026.04.010_bb0350","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cpt.2023.11.005","article-title":"Common endocrine system adverse events associated with immune checkpoint inhibitors","volume":"2","author":"Li","year":"2024","journal-title":"Cancer Pathog. Ther."},{"key":"10.1016\/j.trecan.2026.04.010_bb0355","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.04.010_bb0360","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.acvd.2024.12.005","article-title":"Abatacept dose-finding phase II triaL for immune checkpoint inhibitors myocarditis (ACHLYS) trial design","volume":"118","author":"Salem","year":"2025","journal-title":"Arch. Cardiovasc. Dis."},{"key":"10.1016\/j.trecan.2026.04.010_bb0365","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s44161-025-00640-2","article-title":"Preclinical mouse models of immune checkpoint inhibitor-associated myocarditis","volume":"4","author":"Fankhauser","year":"2025","journal-title":"Nat. Cardiovasc. Res."},{"key":"10.1016\/j.trecan.2026.04.010_bb0370","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jaccao.2025.02.005","article-title":"Immune checkpoint inhibitor\u2013related myocarditis with or without concomitant myopathy: clinical findings and cardiovascular outcomes","volume":"7","author":"Zadok","year":"2025","journal-title":"JACC CardioOncol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0375","doi-asserted-by":"crossref","first-page":"11565","DOI":"10.1038\/s41467-025-67689-2","article-title":"Distinct immune cell dynamics associated with immune-related adverse events during combined chemoradiation and immune checkpoint inhibitor therapy","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.04.010_bb0380","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41591-021-01623-z","article-title":"T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma","volume":"28","author":"Lozano","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.04.010_bb0385","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/imr.13248","article-title":"CD4 T cells and toxicity from immune checkpoint blockade","volume":"318","author":"Earland","year":"2023","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.trecan.2026.04.010_bb0390","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1038\/s41467-017-02358-7","article-title":"TNF\u03b1 blockade overcomes resistance to anti-PD-1 in experimental melanoma","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.04.010_bb0395","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41571-022-00721-2","article-title":"Humanized mouse models for immuno-oncology research","volume":"20","author":"Chuprin","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0400","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.it.2018.07.001","article-title":"Humanized mice for the study of immuno-oncology","volume":"39","author":"De La Rochere","year":"2018","journal-title":"Trends Immunol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0405","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1158\/2326-6066.CIR-23-0498","article-title":"Immune-related colitis is associated with fecal microbial dysbiosis and can be mitigated by fecal microbiota transplantation","volume":"12","author":"Elkrief","year":"2024","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.trecan.2026.04.010_bb0410","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.trecan.2021.02.005","article-title":"Targeting the gut microbiome to mitigate immunotherapy-induced colitis in cancer","volume":"7","author":"Chang","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.trecan.2026.04.010_bb0415","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/s41591-025-04186-5","article-title":"Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial","volume":"32","author":"Duttagupta","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.04.010_bb0420","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jdermsci.2016.12.019","article-title":"Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-\u03b1 is a biomarker of nivolumab reactivity","volume":"86","author":"Tanaka","year":"2017","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.trecan.2026.04.010_bb0425","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/jamadermatol.2015.0249","article-title":"Occurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma","volume":"151","author":"Ohtsuka","year":"2015","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0430","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S1470-2045(24)00278-X","article-title":"Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study","volume":"25","author":"Wan","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0435","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamaoncol.2024.3065","article-title":"Immune checkpoint inhibitor-induced cardiotoxicity: a systematic review and meta-analysis","volume":"10","author":"Nielsen","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0440","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s11912-023-01414-4","article-title":"Risk factors for immune checkpoint inhibitor-mediated cardiovascular toxicities","volume":"25","author":"Yousif","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.trecan.2026.04.010_bb0445","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-217018","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO\u2019s adverse drug reactions database","volume":"81","author":"Nguy\u1ec5n","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.trecan.2026.04.010_bb0450","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/art.41604","article-title":"Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors","volume":"73","author":"Aldrich","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0455","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1344805","article-title":"Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis","volume":"6","author":"Wang","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.trecan.2026.04.010_bb0460","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/ajco.13346","article-title":"Rheumatic immune-related adverse events induced by immune checkpoint inhibitors","volume":"17","author":"Zhong","year":"2021","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0465","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1093\/rheumatology\/keae343","article-title":"Incidence of checkpoint inhibitor-associated inflammatory arthritis, immunomodulation and mortality in cancer patients on immunotherapy: a retrospective cohort study","volume":"64","author":"Bass","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.trecan.2026.04.010_bb0470","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0475","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000063","article-title":"Hepatotoxicity of immune checkpoint inhibitors: what is currently known","volume":"7","author":"Zheng","year":"2023","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.trecan.2026.04.010_bb0480","article-title":"Immune-mediated hepatitis induced by immune checkpoint inhibitors: current updates and future perspectives","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0485","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3892\/ijo.2023.5570","article-title":"Anti-PD-1\/PD-L1 and anti-CTLA-4 associated checkpoint inhibitor pneumonitis in non-small cell lung cancer: occurrence, pathogenesis and risk factors (Review)","volume":"63","author":"Hu","year":"2023","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0490","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3803\/EnM.2023.1785","article-title":"Incidence of endocrine-related dysfunction in patients treated with new immune checkpoint inhibitors: a meta-analysis and comprehensive review","volume":"38","author":"Yoo","year":"2023","journal-title":"Endocrinol. Metab. (Seoul)"},{"key":"10.1016\/j.trecan.2026.04.010_bb0495","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1210\/clinem\/dgaf347","article-title":"Multiple or single endocrine abnormalities associated with immune checkpoint inhibitors","volume":"111","author":"Kamitani","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.trecan.2026.04.010_bb0500","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.3389\/fphar.2019.01453","article-title":"Incidence of immune checkpoint inhibitor-associated diabetes: a meta-analysis of randomized controlled studies","volume":"10","author":"Lu","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0505","doi-asserted-by":"crossref","first-page":"19419","DOI":"10.1038\/s41598-019-56026-5","article-title":"Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French Pharmacovigilance database","volume":"9","author":"Garon-Czmil","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.trecan.2026.04.010_bb0510","doi-asserted-by":"crossref","first-page":"383","DOI":"10.14309\/ajg.0000000000003546","article-title":"Immune-related adverse events are associated with improved outcomes after immune checkpoint inhibitor treatment in hepatocellular carcinoma: a systematic review and meta-analysis","volume":"121","author":"Hwang","year":"2026","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0515","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012358","article-title":"Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes","volume":"13","author":"Aizenbud","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.04.010_bb0520","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.immuni.2025.07.004","article-title":"Naturalized immune responses are stable over years in a colony of laboratory mice with wild-derived microbiota","volume":"58","author":"Oh","year":"2025","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2026.04.010_bb0525","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008482","article-title":"Inhibition of IL-25\/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity","volume":"12","author":"Hu","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.04.010_bb0530","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.132334","article-title":"MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors","volume":"5","author":"Marschner","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.trecan.2026.04.010_bb0535","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41580-020-0259-3","article-title":"Human organoids: model systems for human biology and medicine","volume":"21","author":"Kim","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0540","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41586-024-07791-5","article-title":"Human organoids with an autologous tissue-resident immune compartment","volume":"633","author":"Recaldin","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.04.010_bb0545","article-title":"Assessing personalized responses to anti-PD-1 treatment using patient-derived lung tumor-on-chip","volume":"5","author":"Veith","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.trecan.2026.04.010_bb0550","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aav8995","article-title":"Human CD4+CD103+ cutaneous resident memory T cells are found in the circulation of healthy individuals","volume":"4","author":"Klicznik","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.trecan.2026.04.010_bb0555","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002545","article-title":"Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach","volume":"9","author":"Heilbroner","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.04.010_bb0560","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adj9672","article-title":"Anti-PD-1 cancer immunotherapy induces central nervous system immune-related adverse events by microglia activation","volume":"16","author":"Vinnakota","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2026.04.010_bb0565","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41419-024-07319-9","article-title":"Anti-PD-1 exacerbates bleomycin-induced lung injury in mice via Caspase-3\/GSDME-mediated pyroptosis","volume":"16","author":"Wang","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.trecan.2026.04.010_bb0570","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1002\/ijc.35347","article-title":"How many people in the US are eligible for and respond to checkpoint inhibitors: an empirical analysis","volume":"156","author":"Haslam","year":"2025","journal-title":"Int. J. Cancer"}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326000865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326000865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:45:14Z","timestamp":1788986714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803326000865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":114,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2405803326000865"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2026.04.010","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mouse models of immune-related adverse events: progress, challenges, and opportunities","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2026.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}